All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.
Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).
Jianda Yuan (Merck) to Raphael Clymes (Xencor) to Oncologie to Thomas W Dubensky (ex Immune Design PS Targeting patents w/Merck) may be Tempest to tell how PS Targeting required especially with BGB324 BerGenBio ties to Rolf Brekken / Longen Zhou and many more ...Many well aware especially some new NEW IIS : )
Poster Symposium Time: Location: Co-Chairs: 5:30 – 7:30 p.m. Potomac Ballroom CD Bernard A. Fox, PhD – Earle A. Chiles Research Institute, Providence Cancer Institute Roberta Zappasodi, PhD - Memorial Sloan Kettering Institute
... ...
Session 204: Immune Checkpoints: Newer Targets and Update on Combinations Time: Location: Co-Chairs: 2:00 – 4:20 p.m. Potomac Ballroom Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center Ahmad A. Tarhini, MD, PhD – Moffitt Comprehensive Cancer Center and Research Institute .... ....
5:10 p.m. (O26) A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis Matthew G. Krebs, MD, PhD –The University of Manchester ... ...